Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

No phase data

Trial Status

Completed2

Role Distribution

Principal Investigator2
PI Rate100%

Activity Timeline

Clinical Trials (2)

NCT02751710Not ApplicableCompleted
Impact of 18F-FDG PET-CT Versus Conventional Staging in the Management of Patients Presenting With Clinical Stage III Breast Cancer
Stage IIb Breast Cancer (T3N0)Stage III Breast Cancer (T0N2, T1N2, T2N2, T3N1, 2 or T4)
PrincipalinvestigatorStart date: 2016-12-06
NCT02462239Not ApplicableCompleted
Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging
Muscle-invasive Bladder Cancer
PrincipalinvestigatorStart date: 2016-05-06

Research Network

Collaboration Network

29 collaborators·40 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Research Areas & Affiliations

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Mark Levine, MD

Ontario Clinical Oncology Group (OCOG)

Moderately Similar
13 trials

Shared therapeutic areas:

Muscle-invasive Bladder CancerStage IIb Breast Cancer (T3N0)Stage III Breast Cancer (T0N2, T1N2, T2N2, T3N1, 2 or T4)

Worked with same sponsors:

Cancer Care OntarioOntario Clinical Oncology Group (OCOG)
Collaborated on 2 trials
Similarity Score38%

Ian Dayes, MD

Juravinski Hospital and Cancer Centre

Related
1 trials

Shared therapeutic areas:

Stage IIb Breast Cancer (T3N0)Stage III Breast Cancer (T0N2, T1N2, T2N2, T3N1, 2 or T4)

Worked with same sponsors:

Cancer Care OntarioOntario Clinical Oncology Group (OCOG)
Collaborated on 1 trial
Similarity Score24%

Andrea Eisen, MD

Sunnybrook Health Sciences Centre

Related
2 trials

Shared therapeutic areas:

Stage IIb Breast Cancer (T3N0)Stage III Breast Cancer (T0N2, T1N2, T2N2, T3N1, 2 or T4)

Worked with same sponsors:

Cancer Care OntarioOntario Clinical Oncology Group (OCOG)
Collaborated on 1 trial
Similarity Score24%

Ralph George, MD

St. Michael's Hospital, CIBC Breast Centre

Related
1 trials

Shared therapeutic areas:

Stage IIb Breast Cancer (T3N0)Stage III Breast Cancer (T0N2, T1N2, T2N2, T3N1, 2 or T4)

Worked with same sponsors:

Cancer Care OntarioOntario Clinical Oncology Group (OCOG)
Collaborated on 1 trial
Similarity Score24%

Srikala Sridhar, MD

Princess Margaret Hospital, Canada

Related
1 trials

Shared therapeutic areas:

Muscle-invasive Bladder Cancer

Worked with same sponsors:

Cancer Care OntarioOntario Clinical Oncology Group (OCOG)
Collaborated on 1 trial
Similarity Score14%

Nicholas Power, MD

LHSC-Victoria Hospital

Related
1 trials

Shared therapeutic areas:

Muscle-invasive Bladder Cancer

Worked with same sponsors:

Cancer Care OntarioOntario Clinical Oncology Group (OCOG)
Collaborated on 1 trial
Similarity Score14%

Som Mukherjee, MD

Juravinski Cancer Centre

Related
1 trials

Shared therapeutic areas:

Muscle-invasive Bladder Cancer

Worked with same sponsors:

Cancer Care OntarioOntario Clinical Oncology Group (OCOG)
Collaborated on 1 trial
Similarity Score14%

Won Sik Ham

Department of Urology and Urological Science Institute, Yonsei University College of Medicine Seoul, Republic of Korea

Related
1 trials

Shared therapeutic areas:

Muscle-invasive Bladder Cancer
Similarity Score10%

Julian Schardt, MD

Departement of Medical Oncology, University Hospital Berne

Related
1 trials

Shared therapeutic areas:

Muscle-invasive Bladder Cancer
Similarity Score10%

xiongjun YE

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Related
2 trials

Shared therapeutic areas:

Muscle-invasive Bladder Cancer
Similarity Score10%

Publications (0)

No publications found for this investigator.

Clinical Trials (2)

Showing 2 of 2 trials

NCT02751710Not ApplicablePrincipalInvestigator

Impact of 18F-FDG PET-CT Versus Conventional Staging in the Management of Patients Presenting With Clinical Stage III Breast Cancer

Stage IIb Breast Cancer (T3N0)Stage III Breast Cancer (T0N2, T1N2, T2N2, T3N1, 2 or T4)
Completed
NCT02462239Not ApplicablePrincipalInvestigator

Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging

Muscle-invasive Bladder Cancer
Completed

All 2 trials loaded